This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Beautiful Ecology: the net profit in the first quarter increased by 24.92% to 1.9755 million yuan
The coal sector fell sharply at the opening, and Shanghai Energy fell by the limit
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
Digital Zhengtong: new orders signed in the first two months increased by more than 60% year-on-year
Defining key tasks and accelerating the construction of new urbanization
Shanghai and Shenzhen: The Dual-City Landscape and Corporate Power
Jan 09, 2025 03:35 PM
Under the Fractured Global Supply Chain, How Is United Imaging Shaping a Global "Chain"
Jan 08, 2025 06:10 PM
How AI is Driving Globalization and Transformation in Emerging Industries? | Highlights
Jan 08, 2025 05:44 PM
How Can F&B and Retail Companies Effectively Replicate Local Success Models? | Highlights
Jan 08, 2025 05:09 PM